State Key Laboratory of Virology, College of Life Science, Wuhan University, Wuhan, Hubei 430072, China.
Diagn Microbiol Infect Dis. 2010 Jun;67(2):122-8. doi: 10.1016/j.diagmicrobio.2010.01.009. Epub 2010 Mar 5.
Based on gold-labeled silver stain (GLSS) method, we developed the visual protein microarray for simultaneous, sensitive, and specific detection of Ureaplasma parvum and Chlamydia trachomatis using N-terminus multiple-banded antigen (NMBA) of U. parvum and major outer membrane protein of C. trachomatis. The specific antigens were immobilized on glass surface that was treated with 3-glycidoxypropyltrimethoxysilane, and they were used as the capturing probes to recognize the complementary target antibodies binding to the detecting probes of Nano-gold-Staphylococcal protein A (SPA). In the "sandwich" format, Nano-gold-SPA probe was used as an indicator and GLSS was applied to amplify the detection signals and produce black image on array spots, which were visible with naked eyes. In our model arrays, the detection limit of protein microarray was as low as 2 ng/mL, and the lowest titer of detectable antibody was 1:128; thus, this sensitivity was comparable to the fluorescent detection method. The visual simultaneous protein microarrays were used to detect total 186 clinical samples, which had been determined by enzyme-linked immunosorbent assay (ELISA) and fluorescence quantitative real-time polymerase chain reaction; the results were identical and no distinct difference (P > 0.05) existed between them. Our results demonstrate that we have developed the visual protein microarray technique, which is of high sensitivity and high specificity, and it may have potential in clinical applications.
基于金标记银染(GLSS)方法,我们开发了一种可视化蛋白质微阵列,用于同时、敏感和特异性检测解脲支原体和沙眼衣原体,使用解脲支原体的 N 端多带抗原(NMBA)和沙眼衣原体的主要外膜蛋白。特异性抗原固定在经过 3-缩水甘油氧基丙基三甲氧基硅烷处理的玻璃表面上,作为捕获探针识别互补的目标抗体与纳米金-葡萄球菌蛋白 A(SPA)的检测探针结合。在“三明治”模式下,纳米金-SPA 探针被用作指示剂,GLSS 被用于放大检测信号,并在微阵列点上产生黑色图像,肉眼可见。在我们的模型微阵列中,蛋白质微阵列的检测限低至 2ng/ml,可检测抗体的最低滴度为 1:128;因此,这种灵敏度可与荧光检测方法相媲美。可视化同时蛋白质微阵列用于检测总共 186 个临床样本,这些样本已经通过酶联免疫吸附测定(ELISA)和荧光定量实时聚合酶链反应(PCR)确定;结果相同,无明显差异(P>0.05)。我们的结果表明,我们已经开发出了高灵敏度和高特异性的可视化蛋白质微阵列技术,它可能具有临床应用的潜力。